Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1954 2
1962 1
1963 1
1964 4
1965 2
1966 4
1967 4
1968 3
1969 3
1974 2
1975 3
1976 1
1977 2
1979 1
1980 2
1981 1
1982 1
1983 2
1984 2
1986 4
1987 3
1988 10
1989 5
1990 3
1991 1
1992 4
1993 2
1994 1
1995 1
1996 1
1998 1
1999 1
2001 1
2002 4
2003 7
2004 1
2005 3
2006 1
2007 6
2008 7
2009 6
2010 9
2011 12
2012 13
2013 13
2014 5
2015 11
2016 6
2017 12
2018 7
2019 11
2020 16
2021 14
2022 6
2023 18
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Results by year

Filters applied: . Clear all
Page 1
Skewed X-chromosome inactivation in unsolved neurodevelopmental disease cases can guide re-evaluation For X-linked genes.
Giovenino C, Trajkova S, Pavinato L, Cardaropoli S, Pullano V, Ferrero E, Sukarova-Angelovska E, Carestiato S, Salmin P, Rinninella A, Battaglia A, Bertoli L, Fadda A, Palermo F, Carli D, Mussa A, Dimartino P, Bruselles A, Froukh T, Mandrile G, Pasini B, De Rubeis S, Buxbaum JD, Pippucci T, Tartaglia M, Rossato M, Delledonne M, Ferrero GB, Brusco A. Giovenino C, et al. Among authors: palermo f. Eur J Hum Genet. 2023 Nov;31(11):1228-1236. doi: 10.1038/s41431-023-01324-w. Epub 2023 Mar 6. Eur J Hum Genet. 2023. PMID: 36879111
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
Raimondi A, Nichetti F, Stahler A, Wasan HS, Aranda E, Randon G, Kurreck A, Meade AM, Díaz-Rubio E, Niger M, Stintzing S, Palermo F, Trarbach T, Prisciandaro M, Sommerhäuser G, Fisher D, Morano F, Pietrantonio F, Modest DP. Raimondi A, et al. Among authors: palermo f. Eur J Cancer. 2023 Sep;190:112945. doi: 10.1016/j.ejca.2023.112945. Epub 2023 Jun 19. Eur J Cancer. 2023. PMID: 37441940 Clinical Trial.
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.
Boccaccino A, Rossini D, Raimondi A, Carullo M, Lonardi S, Morano F, Santini D, Tomasello G, Niger M, Zaniboni A, Daniel F, Bustreo S, Procaccio L, Clavarezza M, Cupini S, Libertini M, Palermo F, Pietrantonio F, Cremolini C. Boccaccino A, et al. Among authors: palermo f. Eur J Cancer. 2023 Aug;189:112910. doi: 10.1016/j.ejca.2023.05.001. Epub 2023 May 6. Eur J Cancer. 2023. PMID: 37301718 Clinical Trial.
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.
Morano F, Raimondi A, Pagani F, Lonardi S, Salvatore L, Cremolini C, Murgioni S, Randon G, Palermo F, Antonuzzo L, Pella N, Racca P, Prisciandaro M, Niger M, Corti F, Bergamo F, Zaniboni A, Ratti M, Palazzo M, Cagnazzo C, Calegari MA, Marmorino F, Capone I, Conca E, Busico A, Brich S, Tamborini E, Perrone F, Di Maio M, Milione M, Di Bartolomeo M, de Braud F, Pietrantonio F. Morano F, et al. Among authors: palermo f. J Clin Oncol. 2022 May 10;40(14):1562-1573. doi: 10.1200/JCO.21.02583. Epub 2022 Mar 8. J Clin Oncol. 2022. PMID: 35258987 Free PMC article. Clinical Trial.
242 results